Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CarlsmedFRA:I82 +1.96%20 Return-on-Tangible-Equity is -36.64% as of Mar. 2026. GuruFocus rates FRA:I82 with a GF Score™ of 20/100. The stock has 1 warning sign investors should review. Among 581 Healthcare Providers & Services companies, Carlsmed ranks worse than 92.94% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Carlsmed's annualized net income for the quarter that ended in Mar. 2026 was €-30.09 Mil. Carlsmed's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €82.11 Mil. Therefore, Carlsmed's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -36.64%.
The historical rank and industry rank for Carlsmed's Return-on-Tangible-Equity or its related term are showing as below:
FRA:I82'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -209.88 Med: -209.88 Max: -118.04
Current: -118.04
During the past 3 years, Carlsmed's highest Return-on-Tangible-Equity was -118.04%. The lowest was -209.88%. And the median was -209.88%.
FRA:I82's Return-on-Tangible-Equity is ranked worse than 92.94% of 581
companies
in the Healthcare Providers & Services industry
Industry Median: 10.13
vs FRA:I82: -118.04
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Carlsmed Return-on-Tangible-Equity Related Terms
Carlsmed Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Carlsmed's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:I82 vs SLP, TBRG, SPOK: Return-on-Tangible-Equity Comparison
For the Health Information Services subindustry, Carlsmed's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carlsmed Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Carlsmed's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Carlsmed's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -36.64% mean?
Carlsmed (FRA:I82) has a Return-on-Tangible-Equity of -36.64% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Carlsmed and its competitors. According to the industry distribution chart, Carlsmed ranks #540 out of 581 companies in the Healthcare Providers & Services industry, placing it in the top 92.9%.
Is Carlsmed's Return-on-Tangible-Equity too high?
Carlsmed's current Return-on-Tangible-Equity is -36.64%. Based on the distribution chart, Carlsmed ranks #540 out of 581 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Carlsmed has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Carlsmed's Return-on-Tangible-Equity compare to SLP and TBRG?
According to the Healthcare Providers & Services industry distribution chart, Carlsmed ranks #540 out of 581 companies for Return-on-Tangible-Equity. This places Carlsmed in the lower half of its industry. The industry median Return-on-Tangible-Equity is 10.13. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.13, based on 581 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Carlsmed and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carlsmed's current Return-on-Tangible-Equity is -36.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carlsmed stock overvalued right now?
Carlsmed (FRA:I82) has a current Return-on-Tangible-Equity of -36.64%. The current Return-on-Tangible-Equity is -36.64%. Carlsmed's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Carlsmed (FRA:I82), the current Return-on-Tangible-Equity is -36.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Carlsmed Inc is a commercial-stage medical technology company focused on developing AI-enabled personalized solutions for spine surgery. The company operates as a single operating and reportable segment engaged in the design, manufacture, and marketing of its Aprevo technology platform, which provides customized surgical planning and implants for lumbar and cervical spine fusion procedures, mainly sold to hospitals and ambulatory surgical centers.
20GF Score
Get the complete analysis for FRA:I82
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:I82 has been successfully added to your 
